Silencing the Cytoskeleton Protein Iba1 (Ionized Calcium Binding Adapter Protein 1) Interferes with BV2 Microglia
Roxana-Olimpia Gheorghe1, Alexandru Deftu1, Alexandru Filippi2
1Department of Anatomy, Animal Physiology and Biophysics, Faculty of Biology, University of Bucharest, Splaiul Independentei 91-95, Sector 5, 050095, Bucharest, Romania.
Abstract:
Iba1 (ionized calcium binding adapter protein 1) is a cytoskeleton protein specific only for microglia and macrophages, where it acts as an actin-cross linking protein. Although frequently regarded as a marker of activation, its involvement in cell migration, membrane ruffling, phagocytosis or in microglia remodeling during immunological surveillance of the brain suggest that Iba1 is not a simple cytoskeleton protein, but a signaling molecule involved in specific signaling pathways. In this study we investigated if Iba1 could also represent a drug target, and tested the hypothesis that its specific silencing with customized Iba1-siRNA can modulate microglia functioning. The results showed that Iba1-silenced BV2 microglia migrate less due to reduced proliferation and cell adhesion, while their phagocytic activity and P2x7 functioning was significantly increased. Our data are the proof of concept that Iba1 protein is a new microglia target, which opens a new therapeutic avenue for modulating microglia behavior.
Insights
Ionized calcium binding adapter protein 1 (Iba1) is a novel microglia target. Silencing Iba1 modulates microglia function, impacting migration, adhesion, and phagocytosis, offering new therapeutic strategies.
Area of Science:
- Neuroimmunology
- Cell Biology
Background:
- Ionized calcium binding adapter protein 1 (Iba1) is a cytoskeleton protein primarily found in microglia and macrophages.
- While often considered an activation marker, Iba1's role extends to cell migration, membrane ruffling, phagocytosis, and microglia remodeling during brain immune surveillance, suggesting it functions as a signaling molecule.
Purpose of the Study:
- To investigate if Iba1 can serve as a drug target.
- To test the hypothesis that specific silencing of Iba1 using Iba1-siRNA can modulate microglia functioning.
Main Methods:
- Utilized customized Iba1-small interfering RNA (siRNA) for gene silencing in BV2 microglia cells.
- Assessed changes in microglia migration, proliferation, cell adhesion, phagocytic activity, and P2x7 receptor functioning post-Iba1 silencing.
Main Results:
- Iba1-silenced BV2 microglia exhibited reduced migration, proliferation, and cell adhesion.
- Phagocytic activity and P2x7 receptor functioning were significantly increased in Iba1-silenced microglia.
- Demonstrated that Iba1 plays a crucial role in regulating these specific microglia functions.
Conclusions:
- Iba1 protein represents a new and viable therapeutic target for modulating microglia behavior.
- Specific silencing of Iba1 opens novel therapeutic avenues for conditions involving microglia dysfunction.
